Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals funds independent research and scientific studies focused on cystic fibrosis, pain, IgA nephropathy, and other priority diseases to advance care and knowledge in these areas.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (CF, pain, IgA nephropathy, most grants/sponsorships) | Next cycle opens 2026 (CF Research Innovation Awards, Vertex Innovation Awards, Circle of Care)
Funding Amounts: No strict limits for most grants; CF Research Innovation/Vertex Innovation Awards: up to $750,000 (3 years); Mentored CF RIA: up to $125,000 (2 years). Typically, Vertex will not fund more than 30% of an organization’s annual budget in a year.
Summary: Supports independent research, medical education, patient advocacy, and sponsorships focused on cystic fibrosis and other Vertex priority diseases worldwide.
Key Information: Most programs have rolling deadlines, but select CF awards run annually with next cycles opening in 2026.
Description
Vertex Pharmaceuticals offers a broad portfolio of funding mechanisms to support independent scientific research, medical education, patient advocacy, and organizational sponsorships. The primary focus is on advancing care and knowledge for cystic fibrosis (CF), pain (U.S. only), IgA nephropathy, beta thalassemia, sickle cell disease, and related serious diseases within Vertex’s research priorities. Funding is available for investigator-sponsored studies (ISS), educational grants, patient-centric programs, and sponsorships for relevant events or initiatives.
